13 investors back Bangalore biotech startups in 2026. Bengaluru is India's biotech capital. C-CAMP, BIRAC, and pi Ventures back drug discovery and bio-manufacturing.
Bengaluru is the capital of Indian biotech. It is home to Biocon and the C-CAMP hub.
These funds back drug discovery and bio-manufacturing. They wait years for trials and approvals.
Biotech rounds turn on data, IP, and proof. Ellty tracks every file open when you share your deck.
This guide lists 13 active Bangalore biotech investors below.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| C-CAMP | Bio-incubator | Grants ~US$0.1M-$1M | Drug discovery, genomics, synthetic bio | ccamp.res.in |
| BIRAC | Government biotech agency | Grants ~US$0.05M-$5M | Biopharma, bio-manufacturing, vaccines | birac.nic.in |
| Endiya Partners | Deep-tech / life-sciences VC | US$1M-$5M | Diagnostics, medtech, life sciences | endiya.com |
| pi Ventures | Deep-tech / AI-bio VC | US$1M-$6M | Drug discovery, AI-bio, genomics | piventures.in |
| Omnivore | Agri-food VC | US$1M-$10M | Agri-biotech, crop biologicals, climate bio | omnivore.vc |
| Kotak Life Sciences Fund | Life-sciences PE/VC | US$5M-$20M | Biopharma, biotech, devices | kotakalternateasset.com |
| IKP Knowledge Park | Life-sciences incubator | US$0.05M-$1M | Biopharma, diagnostics, bio-manufacturing | ikpknowledgepark.com |
| Bangalore Bio-Innovation Centre | Government incubator | Incubation / grants | Life sciences, agri-bio, medtech | bioinnovationcentre.com |
| 3one4 Capital | Early-stage VC | US$1M-$10M | Healthtech, diagnostics, deep tech | 3one4capital.com |
| Stellaris Venture Partners | Early-stage VC | US$1M-$10M | Healthtech, digital health, deep tech | stellarisvp.com |
| Capria Ventures | Early-stage VC | US$0.5M-$2M | Healthtech, agritech, climate, AI | capria.vc |
| IvyCap Ventures | Early-stage VC | US$1M-$10M | Healthtech, deep tech, diagnostics | ivycapventures.com |
| Sixth Sense Ventures | Consumer-health VC | US$5M-$20M | Consumer health, pharma, diagnostics | sixthsenseventures.in |
Biotech VCs dig into your science and trials fast. Ellty logs every view in your data room.
Start free 14-day trialA Bangalore biotech investor backs life-science teams. Most are drug, diagnostics, or agri-bio startups.
They write seed to Series B into biotech founders. Pitching Maharashtra investors feels much the same.
They study your science, IP, and your trial data. A strong sales enablement plan helps you later.
Ellty gives each fund one trackable link to your data room. You see who studied your deck before the first call.
We need to create an economy that is full of truly big ideas. Budding entrepreneurs must think big.
C-CAMP is a Bengaluru deep-science bio-incubator.
Recent Activity: Hosted NBEC 2025, awarding Rs 40 Cr to 16 biotech startups
LinkedIn: C-CAMP LinkedIn
Sector Focus: Drug discovery, genomics, synthetic biology
Stage Focus: Pre-seed, seed
Check Size: Grants ~US$0.1M-$1M
Location: Bengaluru
Website: ccamp.res.in
BIRAC is India's government biotech funding agency.
Recent Activity: Launched a Rs 2,000 Cr biotech innovation fund in 2026
LinkedIn: Not listed
Sector Focus: Biopharma, bio-manufacturing, vaccines
Stage Focus: Idea, seed grants
Check Size: Grants ~US$0.05M-$5M
Location: New Delhi / funds Bengaluru
Website: birac.nic.in
Endiya is a deep-tech VC focused on life sciences.
Recent Activity: Saw its portfolio firm Karkinos acquired by Reliance
LinkedIn: Endiya Partners LinkedIn
Sector Focus: Diagnostics, medtech, life sciences
Stage Focus: Seed, Series A
Check Size: US$1M-$5M
Location: Hyderabad / Bengaluru-active
Website: endiya.com
pi Ventures backs AI, biotech, and life sciences.
Recent Activity: Backed immunitoAI in AI antibody and drug discovery
LinkedIn: pi Ventures LinkedIn
Sector Focus: Drug discovery, AI-bio, genomics
Stage Focus: Seed, Series A
Check Size: US$1M-$6M
Location: Bengaluru
Website: piventures.in
Omnivore is an agri-food VC active in agri-biotech.
Recent Activity: First close of a US$150M Fund III and backed BioPrime
LinkedIn: Omnivore LinkedIn
Sector Focus: Agri-biotech, crop biologicals, climate bio
Stage Focus: Seed, Series A
Check Size: US$1M-$10M
Location: Mumbai / Bengaluru-active
Website: omnivore.vc
Ellty shows when C-CAMP or pi Ventures opens your deck. Follow up with each fund at the right time.
Start free 14-day trialKotak runs a dedicated India life-sciences fund.
Recent Activity: First close of a Rs 1,600 Cr fund at Rs 250 Cr in 2025
LinkedIn: Not listed
Sector Focus: Biopharma, biotech, devices
Stage Focus: Early to growth
Check Size: US$5M-$20M
Location: Mumbai / Bengaluru-active
Website: kotakalternateasset.com
IKP is a life-sciences park with a Bangalore site.
Recent Activity: Has supported 1,500+ companies over 25 years
LinkedIn: Not listed
Sector Focus: Biopharma, diagnostics, bio-manufacturing
Stage Focus: Pre-seed, seed
Check Size: US$0.05M-$1M
Location: Hyderabad / Bengaluru
Website: ikpknowledgepark.com
BBC is a Karnataka-government life-sciences incubator.
Recent Activity: An active Bengaluru biotech and agri-bio incubator
LinkedIn: Not listed
Sector Focus: Life sciences, agri-bio, medtech
Stage Focus: Pre-seed, seed
Check Size: Incubation / grants
Location: Bengaluru
Website: bioinnovationcentre.com
3one4 is a Bengaluru VC backing health and deep tech.
Recent Activity: An active Bengaluru healthtech and life-sciences investor
LinkedIn: 3one4 Capital LinkedIn
Sector Focus: Healthtech, diagnostics, deep tech
Stage Focus: Seed, Series A
Check Size: US$1M-$10M
Location: Bengaluru
Website: 3one4capital.com
Stellaris is a Bengaluru VC backing tech and health.
Recent Activity: An active Bengaluru healthtech and life-sciences investor
LinkedIn: Stellaris Venture Partners LinkedIn
Sector Focus: Healthtech, digital health, deep tech
Stage Focus: Seed, Series A
Check Size: US$1M-$10M
Location: Bengaluru
Website: stellarisvp.com
Capria is a Global-South VC active in India health.
Recent Activity: Launched a US$100M India Fund III in late 2024
LinkedIn: Not listed
Sector Focus: Healthtech, agritech, climate, AI
Stage Focus: Seed, pre-Series A
Check Size: US$0.5M-$2M
Location: Bengaluru / Seattle
Website: capria.vc
IvyCap is an India VC with a healthtech portfolio.
Recent Activity: An active India healthtech and deep-tech investor
LinkedIn: IvyCap Ventures LinkedIn
Sector Focus: Healthtech, deep tech, diagnostics
Stage Focus: Seed, Series A/B
Check Size: US$1M-$10M
Location: Mumbai / Bengaluru
Website: ivycapventures.com
Sixth Sense is a consumer VC active in health and pharma.
Recent Activity: An active India consumer-health and pharma investor
LinkedIn: Sixth Sense Ventures LinkedIn
Sector Focus: Consumer health, pharma, diagnostics
Stage Focus: Series A, growth
Check Size: US$5M-$20M
Location: Mumbai / Bengaluru-active
Website: sixthsenseventures.in
Drug discovery and bio-manufacturing draw capital. Bengaluru anchors all of India's biotech base.
Funds want real science, not just a clever idea. Weak data will stall your Series A round fast.
Trial and lab data is highly sensitive to share. Store it all in one secure virtual data room.
Ellty controls who can open each sensitive lab file. You see exactly who studied your data and when.
Biotech lives or dies by trials and approvals. One data gap can stall your whole round fast.
Funds probe your trial design and your patents. Read through our due diligence timeline guide first.
Trial and patent docs are sensitive to share. Lock them all down with strong security controls.
Ellty gates each file and logs every single view. Each fund gets a link you can track and revoke.
Bengaluru holds funds for nearly every biotech stage. C-CAMP and pi Ventures back the earliest rounds.
Each stage wants a bigger and harder proof point. Run a clean due diligence process right from day one.
Know the gap between hard and soft due diligence. It shapes what each fund will end up asking for.
Ellty logs who opened each file and exactly when. You can follow up at the right moment every time.
Lead with your science, IP, and trial data.
You've shortlisted your Bangalore biotech investors already. Set up a data room before the first call.


